TO: [PATIENT NAME]  
Subject: Update to [06/18/24] NovoSeven® RT (coagulation Factor VIIa, recombinant) Supply Communication: NEW TIMELINE

Dear [PATIENT NAME],

In keeping with their commitment to share new information regarding product supply when it becomes available, we are reaching out to provide you with the latest update on the availability of NovoSeven® RT (coagulation Factor VIIa, recombinant) that I've received from Novo Nordisk, the company that makes the medicine.

- Novo Nordisk has made the determination to give FDA 5 business days to respond to the recent issue impacting supply of NovoSeven® RT supply, and this has resulted in a slight shift in the timeline for release and availability of products at their distribution center.
- The changes in availability per strength are as follows:
  - 1 mg: The 1 mg vial was originally expected to be available by June 24, 2024. It has been released and is in transit to the U.S. It is now expected to be available by June 27, 2024.
  - 2 mg: The 2 mg vial was originally expected to be available by June 17, 2024. It is now expected to be available by June 24, 2024.
  - 8 mg: The 8 mg vial will back in stock by June 24, 2024. Its availability is not related to the underfilling issue associated with the 1 mg and 2 mg.
  - 5 mg: Remains fully available.

Novo Nordisk recognizes this is a very challenging time for you, your caregivers, and the community. Please know that Novo Nordisk is working as quickly as possible to resolve the current issue and will continue to communicate with transparency and as updates are available.

Thank you and please know our care team is here to support you in your treatment journey.

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning. NovoSeven RT PI (novo-pi.com).
Sincerely,

[Sender]